Lv7
4010 积分 2021-03-22 加入
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
12天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
20天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
NSCLC: Five trials to watch
2个月前
已完结
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
5个月前
已完结
Navigating the Evolving Landscape of EGFR-Mutated NSCLC
6个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
6个月前
已完结
Patterns and preoperative risk factors of occult lymph node metastasis in clinical stage I lung cancer
6个月前
已完结
Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis
7个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
10个月前
已完结
皖公网安备34019202002308
